CNSP
CNS Pharmaceuticals·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 0
Consensus Rating "Strong Buy"
Ample Liquidity
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CNSP
Cns Pharmaceuticals, Inc.
A company that developing anticancer drug candidates for the treatment of brain and central nervous system tumors
2100 West Loop South, Suite 900, Houston, TX 77027
--
CNS Pharmaceuticals, Inc.is a clinical pharmaceutical company formed on July 27, 2017 as a Nevada company focused on the development of anticancer drug candidates for the treatment of brain and central nervous system tumors, The Company is based on intellectual property licensed under license agreements with Houston Pharma Corporation (" HPI ") and The University of Texas MD Anderson Cancer Center (" UTMDACC ") and owned under a collaboration and asset purchase agreement with Reata Pharmaceuticals, Inc. (" Reata ").
Company Financials
EPS
CNSP has released its 2025 Q2 earnings. EPS was reported at -6.42, versus the expected -0.8, missing expectations. The chart below visualizes how CNSP has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
